Q-omics provides the consensus-scored FTLP1 profile across patient tissues and cancer cell-line models. FTLP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FTLP1 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, FTLP1 RNA expression shows 9,129 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRP, and TGCT as cancer lineages where FTLP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP1 survival associations across molecular data types. FTLP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP1 RNA expression–survival associations across cancer types. High FTLP1 expression shows unfavorable associations in MESO, LGG, LIHC and STAD, but favorable associations in CESC and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FTLP1 RNA expression.
This table summarizes FTLP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP1 shows lower tumor expression in KIRP, KICH, LUSC and PAAD and higher tumor expression in STAD and HNSC. The KIRP box plot shows higher FTLP1 RNA expression in normal versus tumor tissue (log2 FC = −0.207, t-test p = .009).
This table shows molecular features associated with FTLP1 in patient tissues and cancer cell lines. In patient samples, FTLP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
